COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made the 23rd. day of May, 2011 (“EFFECTIVE DATE”) by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not-for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America (“LICR”) and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland at Schwarzwaldallee 215, CH-4002 Basel, Switzerland.
Commercial Lease Agreement No. 01/2003Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
SUBLEASE AGREEMENTSublease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
Item Subject Page(s) – Contract parties / Leased property 3 1 Type of use 4 2 Sublease 4 3 Start of lease / Duration of lease / Termination 4 4 Rent / Incidental expenses / Payment deadline 5 5 Security deposit 5 6 Rent adjustments / Index clause 5/6 7 Heating and incidental expenses 6/7 8 Handover 7 9 Use of the leased property / Order 7/8 10 Structural changes 8/9 11 Builder’s lien 9 12 Addresses / Advertising signs 10 13 Upkeep / Repairs / Defects 10 14 Permits 10 15 Insurances / Risk 10/11 16 Right of access 11 17 Keys 11 18 Return of the leased property 11/12 19 Expansion 12 20 Address for delivery 12/13 21 Written form / Subsidiary right / Place of jurisdiction 13 22 Transfer of sublease relationship 13
COLLABORATIVE RESEARCH & DEVELOPMENT AND COMMERCIAL RIGHTS AGREEMENTCollaborative Research & Development and Commercial Rights Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATIVE RESEARCH & DEVELOPMENT AND COMMERCIAL RIGHTS AGREEMENT (this “AGREEMENT”) is made the 21st day of December, 2012 (“EFFECTIVE DATE”) by and between RECEPTA BIOPHARMA S.A. with its principal place of business at Rua Tabapuã 1123, cj 36, Sao Paulo, SP Brazil, enrolled with the CNPJ/MF under No. CNPJ/MF: 07.896.151/0001-19, with its By-laws duly filed with the Commercial Registry of the State of São Paulo – JUCESP under NIRE 35.300.329.287 (“RECEPTA”), the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not- for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America (“LICR”), and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland with its registered office at Hochbergerstrasse 60C, CH-4057 Basel, Switzerland. RECEPTA, LICR, and 4AB may each be referred to herein, individually, as a “PARTY” or, collectively, as the “PARTIES”.
29th Addendum to Lease Agreement No. 01/2003 from 12/01/2002Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
Addendum to the Lease Agreement from 01/28/2011 between 4-Antibody AG, Hochbergerstr. 60C, 4057 Basel (Sublessee) and Technologie Park Basel AG, c/o Amt für Wirtschaft und Arbeit [Office for Economy and Labor], Utengasse 36, 4005 Basel (Principal Lessee)Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
The two parties named above declare that the following spaces are added to the leased spaces in Technologie Park Basel (Hochbergerstrasse 60C, 4057 Basel) as of 03/31/2012:
28th Addendum to Lease Agreement No. 01/2003 from 12/01/2002Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
amend the above-mentioned Lease Agreement on the basis of the approval of the State Administration Office of Thuringia per e-mail from 06/07/2013 (copy in Annex 1 to this Addendum) as follows:
20th Addendum to Lease Agreement No. 01/2003 from 12/01/2002Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
amend the above-mentioned Lease Agreement on the basis of the application of BioCentiv GmbH to the State Administration Office of Thuringia from 09/08/2010 (Annex 1 to this Addendum) and its approval from 10/05/2010 (Annex 2 to this Addendum) as follows:
Addendum No. 4 to the Lease Agreement from 01/28/2011 between 4-Antibody AG, Hochbergerstr. 60C, 4057 Basel (Sublessee) and Technologie Park Basel AG, Hochbergerstr. 60C, 4057 Basel (Principal Lessee)Lease Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances)
The parties mentioned above agree as follows with regard to the maintenance of air-conditioners in the rooms rented by 4-Antibody AG and concerning the provision of the autoclave and ice machine to other tenants of Technologie Park Basel:
